Walter M. Gregory

15.9k total citations
203 papers, 9.3k citations indexed

About

Walter M. Gregory is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Walter M. Gregory has authored 203 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 101 papers in Hematology and 67 papers in Molecular Biology. Recurrent topics in Walter M. Gregory's work include Multiple Myeloma Research and Treatments (88 papers), Protein Degradation and Inhibitors (44 papers) and Cancer Treatment and Pharmacology (34 papers). Walter M. Gregory is often cited by papers focused on Multiple Myeloma Research and Treatments (88 papers), Protein Degradation and Inhibitors (44 papers) and Cancer Treatment and Pharmacology (34 papers). Walter M. Gregory collaborates with scholars based in United Kingdom, United States and Italy. Walter M. Gregory's co-authors include Gareth J. Morgan, Faith E. Davies, Graham Jackson, Roger G. Owen, Mark T. Drayson, Sue Bell, Gordon Cook, J. Anthony Child, Fiona M. Ross and Roger Buckley and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Walter M. Gregory

198 papers receiving 9.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Walter M. Gregory 4.0k 3.9k 3.9k 1.3k 1.2k 203 9.3k
Bronno van der Holt 3.1k 0.8× 3.0k 0.8× 2.1k 0.5× 1.2k 0.9× 536 0.5× 224 7.8k
D Maraninchi 3.7k 0.9× 3.8k 1.0× 1.3k 0.3× 1.4k 1.0× 816 0.7× 259 8.5k
Jerry A. Katzmann 5.4k 1.4× 2.6k 0.7× 5.1k 1.3× 1.4k 1.1× 1.2k 1.0× 171 10.6k
Xuemei Wang 2.8k 0.7× 2.8k 0.7× 2.1k 0.5× 1.4k 1.1× 549 0.5× 252 10.4k
Sonja Zweegman 6.5k 1.6× 4.6k 1.2× 5.1k 1.3× 574 0.4× 768 0.7× 334 10.4k
Edward A. Stadtmauer 6.7k 1.7× 6.9k 1.8× 5.2k 1.3× 2.3k 1.7× 739 0.6× 331 14.0k
Seema Singhal 7.0k 1.8× 4.0k 1.0× 4.6k 1.2× 677 0.5× 349 0.3× 291 10.7k
Martin F. Fey 2.1k 0.5× 3.0k 0.8× 3.1k 0.8× 1.2k 0.9× 229 0.2× 189 8.0k
Rochelle E. Curtis 2.2k 0.5× 4.3k 1.1× 1.1k 0.3× 2.7k 2.0× 1.1k 0.9× 109 11.2k
Michèle Cavo 11.3k 2.8× 6.7k 1.7× 7.7k 2.0× 957 0.7× 741 0.6× 557 14.5k

Countries citing papers authored by Walter M. Gregory

Since Specialization
Citations

This map shows the geographic impact of Walter M. Gregory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter M. Gregory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter M. Gregory more than expected).

Fields of papers citing papers by Walter M. Gregory

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter M. Gregory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter M. Gregory. The network helps show where Walter M. Gregory may publish in the future.

Co-authorship network of co-authors of Walter M. Gregory

This figure shows the co-authorship network connecting the top 25 collaborators of Walter M. Gregory. A scholar is included among the top collaborators of Walter M. Gregory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter M. Gregory. Walter M. Gregory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gregory, Walter M., Thomas J. Prior, Pieter Sonneveld, et al.. (2025). Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential. Clinical Cancer Research. 31(11). 2154–2161.
2.
3.
Jenner, Matthew, Charlotte Pawlyn, Faith E. Davies, et al.. (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology. 201(2). 267–279. 11 indexed citations
4.
Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900. 40 indexed citations
5.
Tulotta, Claudia, Diane V. Lefley, Walter M. Gregory, et al.. (2019). Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clinical Cancer Research. 25(9). 2769–2782. 136 indexed citations
6.
Ubellacker, Jessalyn M., Ninib Baryawno, Nicolas Sévère, et al.. (2018). Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. Cancer Research. 78(18). 5300–5314. 23 indexed citations
7.
Wah, Tze Min, Steven Sourbron, Daniel J. Wilson, et al.. (2018). Renal Cell Carcinoma Perfusion before and after Radiofrequency Ablation Measured with Dynamic Contrast Enhanced MRI: A Pilot Study. Diagnostics. 8(1). 3–3. 6 indexed citations
8.
Sherborne, Amy L., Vallari Shah, Sidra Ellis, et al.. (2017). Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. Blood. 130. 1767–1767. 2 indexed citations
9.
Pawlyn, Charlotte, Martin Kaiser, David A. Cairns, et al.. (2017). Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial. Blood. 130. 3040–3040. 2 indexed citations
10.
Franks, K., M. Snee, Babu Naidu, et al.. (2017). P1.05-029 SABRTOOTH-A Feasibility Study of SABR Compared to Surgery in Patients with Peripheral Stage I NSCLC Considered to Be at Higher Risk from Surgery. Journal of Thoracic Oncology. 12(1). S631–S632. 1 indexed citations
11.
Kuiper, Rowan, Mark van Duin, Martin H. van Vliet, et al.. (2015). Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood. 126(17). 1996–2004. 77 indexed citations
12.
Wu, Ping, Brian A. Walker, Daniel Brewer, et al.. (2011). A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment. Clinical Cancer Research. 17(19). 6347–6355. 18 indexed citations
13.
Boyd, Kevin, Fiona M. Ross, Brian A. Walker, et al.. (2011). Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. Clinical Cancer Research. 17(24). 7776–7784. 131 indexed citations
14.
Boyd, Kevin, Fiona M. Ross, Laura Chiecchio, et al.. (2011). Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1703–1707. 33 indexed citations
15.
Kelly, Richard, Anita Hill, Louise Arnold, et al.. (2011). Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 117(25). 6786–6792. 347 indexed citations
16.
Dickens, Nicholas J., Brian A. Walker, Paola Leone, et al.. (2010). Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clinical Cancer Research. 16(6). 1856–1864. 85 indexed citations
17.
Craven, Rachel A., D. Cohen, Claire Taylor, et al.. (2009). Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clinical Cancer Research. 15(24). 7582–7592. 137 indexed citations
18.
Platt, Fiona M., Carolyn D. Hurst, Claire Taylor, et al.. (2009). Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer. Clinical Cancer Research. 15(19). 6008–6017. 202 indexed citations
19.
Bobrow, Lynda G., Lisa Happerfield, Walter M. Gregory, & Rosemary R. Millis. (1995). Ductal carcinoma in situ: Assessment of necrosis and nuclear morphology and their association with biological markers. The Journal of Pathology. 176(4). 333–341. 43 indexed citations
20.
Bobrow, Lynda G., et al.. (1994). The classification of ductal carcinoma in situ and its association with biological markers.. PubMed. 11(3). 199–207. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bronno van der Holt Breakdown of academic impact, for papers by D Maraninchi Breakdown of academic impact, for papers by Jerry A. Katzmann Breakdown of academic impact, for papers by Xuemei Wang Breakdown of academic impact, for papers by Sonja Zweegman Breakdown of academic impact, for papers by Edward A. Stadtmauer Breakdown of academic impact, for papers by Seema Singhal Breakdown of academic impact, for papers by Martin F. Fey Breakdown of academic impact, for papers by Rochelle E. Curtis Breakdown of academic impact, for papers by Michèle Cavo
Rankless by CCL
2026